Etravirine: A second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 692-704

  Schiller, Daryl S ^a   Youssef Bessler, Manal ^a  

^a SAINT BARNABAS MEDICAL CENTER   (United States)

Author keywords

etravirine; human immunodeficiency virus; nonnucleoside reverse transcriptase inhibitor; resistance; TMC125; treatment experienced

Indexed keywords

AMPRENAVIR PHOSPHATE; ATAZANAVIR; BENZODIAZEPINE DERIVATIVE; CALCIUM CHANNEL BLOCKING AGENT; CYCLOSPORIN; DARUNAVIR; DARUNAVIR PLUS RITONAVIR; DELAVIRDINE; DISOPYRAMIDE; DOCETAXEL; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDINAVIR; LIDOCAINE; MACROGOL 4000; MOXIFLOXACIN; NEVIRAPINE; PACLITAXEL; PROTEINASE INHIBITOR; QUINIDINE; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SILDENAFIL; TACROLIMUS; TIPRANAVIR; TRICYCLIC ANTIDEPRESSANT AGENT; VINCA ALKALOID;

ANTIVIRAL THERAPY; ANXIETY; CELL COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ABSORPTION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG WITHDRAWAL; GENE MUTATION; HEADACHE; HOSPITAL COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER DISEASE; LOW DRUG DOSE; MULTIDRUG RESISTANCE; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PANCREATITIS; PERIPHERAL NEUROPATHY; QT PROLONGATION; RASH; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; TABLET FORMULATION; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PYRIDAZINES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 65549107808     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.020     Document Type: Review

References (49)

1. Centers for Disease Control (CDC). Pneumocystis pneumonia-Los Angeles. MMWR Morb Mortal Wkly Rep. 30 (1981) 250-252
2. Joint United Nations Programme on HIV/AIDS, World Health Organization (UNAIDS, WHO). Global summary of the AIDS epidemic. [UNAIDS Web site]. (December 2007). http://data.unaids.org/pub/EPISlides/2007/2007_epiupdate_en.pdf Accessed December 10, 2008.
3. Centers for Disease Control (CDC). New estimates of US HIV prevalence (2006). http://www.cdc.gov/hiv/topics/surveillance/resources/factsheets/pdf/prevalence.pdf Accessed December 10, 2008.
4. Hirschel B., and Francioli P. Progress and problems in the fight against AIDS. N Engl J Med 338 (1998) 906-908
5. Panel on Antiretroviral Guidelines for Adults and Adolescents (AIDSinfo). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Dept of Health and Human Services (November 3, 2008) 1-139. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf Accessed December 10, 2008.
6. Hammer S.M., Eron Jr. J.J., Reiss P., et al., the International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 Recommendations of the International AIDS Society-USA panel. JAMA 300 (2008) 555-570
7. De Corte B.L. From 4,5,6,7-tetrahydro-5-methylimidazo [4,5,1-jk](1,4)benzodiazepin-2(1H)-one (TIBO) to etravirine (TMC125): Fifteen years of research on non-nucleoside inhibitors of HIV-1 reverse transcriptase. J Med Chem. 48 (2005) 1689-1696
8. Cahn P., Haubrich R., Leider J., et al. Pooled 24-week results of DUET-1 and -2: TMC125 (etravirine; ETR) vs placebo in 1203 treatment-experienced HIV-1-infected patients. Presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, Ill (September 17-20, 2007) Abstract H-717
9. di Marzo Veronese F., Copeland T.D., DeVico A.L., et al. Characterization of highly immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV. Science 231 (1986) 1289-1291
10. Tachedjian G., Orlova M., Sarafianos S.G., et al. Nonnucleo-side reverse transcriptase inhibitors are chemical enhanc- ers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci U S A 98 (2001) 7188-7193
11. Intelence [package insert] (2008), Tibotec Therapeutics, Division of Ortho Biotech Products, LP, Raritan, NJ. http://www.intelence-info.com/intelence/assets/pdf/INTELENCE_PI.pdf Accessed December 10, 2008
12. Das K., Clark Jr. A.D., Lewi P.J., et al. Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etra-virine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants. J Med Chem 47 (2004) 2550-2560
13. Andries K., Azijn H., Thielemans T., et al. TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleo-side reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemo- ther 48 (2004) 4680-4686
14. Vingerhoets J., Peeters M., Azijn H., et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): Multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Presented at: XVII International HIV Drug Resistance Workshop. Sitges, Spain (June 10-14, 2008). http://www.natap.org/2008/ResisWksp/ResisWksp_47.htm Accessed December 10, 2008
15. Vingerhoets J., Azijn H., Fransen E., et al. TMC125 displays a high genetic barrier to the development of resistance: Evidence from in vitro selection experiments. J Virol. 79 (2005) 12773-12782
16. Haubrich R., Schapiro J.M., Vinger-hoets J., et al. Combined darunavir and etravirine resistance analysis of the pooled DUET trials: When can we spare the other new classes?. Presented at: XVII International AIDS Conference. Mexico City, Mexico (August 3-8, 2008). http://www.tibotec.com/content/congresses/www.tibotec.com/Haubrich_TMC125_pDUET_Ran.pdf Accessed December 10, 2008
17. Madruga J.V., Cahn P., Grinsztejn B., et al., the DUET-1 Study Group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-Week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (2007) 29-38
18. Lazzarin A., Campbell T., Clotet B., et al., the DUET-2 Study Group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-Week results from a randomized, double-blind, placebo-controlled trial. Lancet 370 (2007) 39-48
19. Llibre J.M., Santos J.R., Puig T., et al. Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efa-virenz. J Antimicrob Chemother 62 (2008) 909-913
20. Scholler M., Hoetelmans R., Beets G., et al. Substantial improvement of oral bioavailability of TMC125 using new tablet formulations in healthy volunteers. Presented at: 3rd International AIDS Conference. Rio de Janeiro, Brazil (July 24-27, 2005). http://www.natap.org/2005/ias/ias_17.htm Accessed December 10, 2008
21. Boffito M., Winston A., Jackson A., et al. Pharmacokinetics and antiretro-viral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance. AIDS 21 (2007) 1449-1455
22. Kakuda T.N., Wade J.R., Snoeck E., et al. Pharmacokinetics and pharma-codynamics of the NNRTI etravir-ine (ETR; TMC125) in treatment-experienced HIV-1-infected patients: Pooled 24-week results of DUET-1 and DUET-2. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, Mass (February 3-6, 2008). http://www.hivandhepatitis.org/2008icr/croi/docs/posters/Kakuda2.pdf Accessed December 10, 2008
23. Raaoof A., Mannens G., Annaert R., et al. Interspecies comparison of the in vitro metabolism of the anti-HIV compound TMC125. Presented at: 7th Annual Meeting of the American Association of Pharmaceutical Scientists. San Antonio, Tex (October 29-November 2, 2006) Abstract M1314
24. Seminari E., Castagna A., and Lazzarin A. Etravirine for the treatment of HIV infection. Expert Rev Anti Infect Ther 6 (2008) 427-433
25. Raoof A., Mannens G., Mamidi R., et al. In vivo metabolism and mass balance of the anti-HIV compound TMC125 in laboratory animals and healthy volunteers. Presented at: 7th Annual Meeting of the American Association of Pharmaceutical Scientists. San Antonio, Tex (October 29-November 2, 2006) Abstract M1342
26. Piscitelli S., Baede P., DeDier K., et al. Pharmacokinetics of TMC125 in HIV-infected patients and healthy volunteers. Presented at: 3rd International Workshop on Clinical Pharmacology of HIV Therapy. Washington, DC (April 11-13, 2002) Abstract 6.1
27. Schöller-Gyüre M., Kakuda T.N., De Smedt G., et al. A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. Br J Clin Pharmacol 66 (2008) 508-516
28. Schöller-Gyüre M., Boffito M., Pozniak A.L., et al. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine. Pharmacotherapy 28 (2008) 1215-1222
29. Kakuda T.N., Schöller-Gyüe M., Peeters M., et al. Pharmacokinetics of etravirine are not affected by sex, age, race, treatment duration or use of enfuvirtide in HIV-1-infected subjects. Presented at: XVII International AIDS Conference. Mexico City, Mexico (August 3-8, 2008). http://www.medadvocates.org/resources/conferences/international_aids_conferences/17/etravirine/aa17KakudaPoster_FINAL.pdf Accessed December 10, 2008
30. Kakuda T.N., Schöller-Gyüre M., Peeters M., et al. Pharmacokinetics and pharmacodynamics ofTMC125 in HIV-infected patients with non-nucleoside reverse transcriptase inhibitor and protease inhibitor resistance: TMC125-C223. Presented at: 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, Calif (February 25-28, 2007)
31. Gruzdev B., Rakhmanova A., Dou-bovskaya E., et al. A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monothera-py in antiretroviral naive, HIV-1 infected subjects. AIDS 17 (2003) 2487-2494
32. Gazzard B.G., Pozniak A.L., Rosenbaum W., et al. An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17 (2003) F49-F54
33. Montaner J., Yeni P., Clumeck N.N., et al., the TMC125-C203 Study Group. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase IIb doseranging study involving treatment-experienced patients with HIV-1 infection. Clin Infect Dis 47 (2008) 969-978
34. Nadler J.P., Berger D.S., Blick G., et al., the TMC125-C223 Writing Group. Efficacy and safety of etra-virine (TMC125) in patients with highly resistant HIV-1: Primary 24- week analysis. AIDS 21 (2007) F1-F10
35. Haubrich R., Cahn P., Grinsztejn B., et al., the DUET-1 Study Group. DUET-1: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETR; TMC125) versus pla- cebo in 612 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, Mass (February 3-6, 2008). http:// www.natap.org/2008/CROI/croi_38.htm Accessed December 10, 2008
36. Johnson M., Campbell T., Clotet B., et al. DUET-2: Week 48 results of a Phase III randomized double-blind trial to evaluate the efficacy and safety of etravirine (ETRl TMC125) versus placebo in 591 treatment-experienced HIV-1-infected patients. Presented at: 15th Conference on Retroviruses and Opportunistic Infections. Boston, Mass (February 3-6, 2008) Abstract 791
37. Haubrich R., Schechter M., Walms-ley S., et al. TMC125 safety and tol-erability in treatment-experienced, HIV infected patients-pooled DUET trial data. Presented at: 45th Annual Meeting of the Infectious Diseases Society of America. San Diego, Calif (October 4-7, 2007). CKey={D712B83E-A1E0-4C21-B9E9-D1445F892115}& MKey={2BC0388C-EE56-4FA2-A529-EC8 2E2C73 62A}&AKey={45 6A 1804-CC97-4677-BF53-D872148C 9EF7}& SKey={07A115CE-07- A8-4EB9-A4CC-D64DFF340C90}. Accessed December 10, 2008 http:// www.abstractsonline.com/viewer/ viewAbstract.asp
38. Peeters M., Janssen K., Kakuda T.N., et al. Etravirine has no effect on QT and corrected QT interval in HIVnegative volunteers. Ann Pharmaco- ther 42 (2008) 757-765
39. Kakuda T.N., Schöller-Gyüre M., Woodfall B., et al. TMC125 in combination with other medications: Summary of drug-drug interaction studies. Presented at: 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (November 12-16, 2006). http://www.tibotec.com/content/congresses/www.tibotec.com/Kakuda_TMC125_DDI.pdf Accessed December 10, 008
40. Schöller-Gyüre M., Woodfall B., De Marez T., et al. Pharmacokinetics of TMC125 with atazanavir and atazanavir/ritonavir. Presented at: 8th International Congress on Drug Therapy in HIV Infection. Glasgow, UK (November 12-16, 2006)
41. Baede P., Piscitelli S., Graham N., and Van't Klooster G. Drug interactions with TMC125, a potent next generation NNRTI. Presented at: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, Calif (September 27-30, 2002). http://gateway.nlm.nih.gov/MeetingAbstracts/ma?f=102266562.html Accessed December 10, 2008. Abstract A-1827
42. Schöller M., Kraft M., Hoetelmans R., et al. Significant decrease in TMC125 exposures when co-administered with tipranavir boosted with ritona-vir in healthy subjects. Presented at: 13th Conference on Retroviruses and Opportunistic Infections. Denver, Col (February 5-8, 2006). http://www.retroconference.org/2006/Abstracts/27489.HTM Accessed December 10, 2008
43. Michalets E.L. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 18 (1998) 84-112
44. Schöller-Gyüre M., Kakuda T.N., Van Solingen-Ristea R.M., et al. Bioavail-ability of the 100mg etravirine tablet dispersed in water and of the 25mg pediatric tablet formulation. Presented at: XVII International AIDS Conference. Mexico City, Mexico (August 3-8, 2008). http://www.iasociety.org/abstractmaterial/AIDS2008/AbstractPlus/AbsDoc_6021_2.pdf Accessed December 10, 2008
45. Sendi P., Palmer A.J., Gafni A., and Battegay M. Highly active antiretroviral therapy: Pharmacoeconomic issues in the management of HIV infection. Pharmaco Economics. 19 (2001) 709-713
46. Martin S., and Hill A.M. Analysis of US costs of full virologic suppression for treatment-experienced, HIV- infected patients in the DUET trials. Presented at: XVII International AIDS Conference. Mexico City, Mexico (August 3-8, 2008) Abstract TUPE0241
47. Gebo K., Martin S., Corbett C., and De Smedt G. Impact of etravirine on hospitalizations and hospital-related costs: 48-Week findings from pooled DUET trials. Presented at: XVII International AIDS Conference. Mexico City, Mexico (August 3-8, 2008). http://www.medadvocates.org/resources/conferences/international_aids_conferences/17/etravirine/aaa17GeboPoster_FINAL.pdf Accessed December 10, 2008
48. Yazdanpanah Y., Fagard C., Descamps D., et al. High rate of viro-logic success with raltegravir plus etravirine and darunavir/ritonavir in treatment-experienced patients with multidrug-resistant virus: Results of the ANRS 139 TRIO trial. XVII International AIDS Conference. Mexico City, Mexico (2008). http://www.hivandhepatitis.com/2008icr/AIDS2008/docs/081508_a.html Accessed April 10, 2009
49. Di Perri G., Madruga J.V., Sathasivam K., et al. The impact of background regimen on virologic response to etravirine: Pooled 48-week analysis of DUET-1 and DUET-2. Presented at: XVII International AIDS Conference. Mexico City, Mexico (August 3-8, 2008). http://www.medadvocates.org/resources/conferences/international_aids_conferences/17/etravirine/aa171DiPerriPoster_FINAL.pdf Accessed December 10, 2008